About Invuity (NASDAQ:IVTY)
Invuity, Inc., a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges. It offers various illuminated surgical devices, including Eikon LT Illuminated and Eikon illuminated retractor systems for breast oncology/oncoplastic/general/orthopedics surgeries; Saber Yankauer, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general surgeries; and Saber Frazier, a handheld illuminator for spine/orthopedic/neurosurgery surgeries. The company also provides Eika illuminated retractor systems for anterior neck approaches comprising thyroid and cervical spine surgeries; Breiten illuminated retractor systems for spine surgeries; Eipex illuminated retractor systems for spine/orthopedic surgeries; Eivector illuminated and Eiberg Illuminated retractor systems for orthopedic surgeries; and Waveguide XT system, a drop-in intracavity illuminator for spine surgeries. Invuity, Inc. sells its devices through its direct sales representatives and independent sales agents; and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. The company was formerly known as Spotlight Surgical, Inc. and changed its name to Invuity, Inc. in 2007. Invuity, Inc. was incorporated in 2004 and is based in San Francisco, California.
Industry, Sector and Symbol:
- Industry: Medical Instruments & Supplies
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:IVTY
- CUSIP: N/A
- Web: www.invuity.com
- Debt-to-Equity Ratio: 5.39%
- Current Ratio: 2.90%
- Quick Ratio: 2.47%
Sales & Book Value:
- Annual Sales: $32.46 million
- Price / Sales: 4.25
- Book Value: $0.31 per share
- Price / Book: 25.97
- Trailing EPS: ($2.47)
- Net Income: ($40,600,000.00)
- Net Margins: -111.43%
- Return on Equity: -212.38%
- Return on Assets: -73.58%
- Employees: 172
- Outstanding Shares: 17,140,000
Frequently Asked Questions for Invuity (NASDAQ:IVTY)
What is Invuity's stock symbol?
Invuity trades on the NASDAQ under the ticker symbol "IVTY."
How were Invuity's earnings last quarter?
Invuity, Inc. (NASDAQ:IVTY) issued its quarterly earnings results on Tuesday, November, 7th. The medical instruments supplier reported ($0.52) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.56) by $0.04. The medical instruments supplier had revenue of $9.60 million for the quarter, compared to analyst estimates of $9.87 million. Invuity had a negative return on equity of 212.38% and a negative net margin of 111.43%. View Invuity's Earnings History.
When will Invuity make its next earnings announcement?
Where is Invuity's stock going? Where will Invuity's stock price be in 2017?
4 brokerages have issued 12 month price targets for Invuity's shares. Their forecasts range from $10.00 to $13.00. On average, they expect Invuity's stock price to reach $11.67 in the next year. View Analyst Ratings for Invuity.
What are Wall Street analysts saying about Invuity stock?
Here are some recent quotes from research analysts about Invuity stock:
- 1. According to Zacks Investment Research, "Invuity, Inc. is a medical technology company. Its products include Eikon Illuminated Retractor System, Saber Yankauer, Saber Frazier, Eika Illuminated Retractor System, Breiten Illuminated Retractor System, Eipex Illuminated Retractor System, Eivector Illuminated Retractor System and Waveguide XT System. The Company sells its devices through its direct sales representatives and original equipment manufacturers of surgical systems. Invuity, Inc. is based in San Francisco, California. " (10/4/2017)
- 2. Stifel Nicolaus analysts commented, "Following Invuity's early January top-line pre-announcement giving a potential $9.1M-$9.3M revenue range, the company's full 4Q16 release and call provided both more positive details on the quarter and critical revenue measures, all of which suggests the business has stabilized after slower than expected 3Q16 results. At $9.4M, 4Q16 sales were a touch ahead of the company's preliminary range. Encouragingly, revenue per account at $12,100 (+10% Y/Y, 5% Q/Q) -- a critical measure for assessing the company's "go-deep" strategy -- appears stable. Equally impressive, the company continued to expand its active hospital account base which now stands at 745 (+41% Y/Y). Management again reaffirmed 2017 top-line guidance of $42M-$44M, which, in our view, could prove conservative given 4Q16 stable revenue/account, new accounts adds, and "modest" contribution from the mid-year 2017 expected full launch of PhotonBlade. We continue to believe Invuity's highly differentiated, and expanding, portfolio of procedure enhancing technologies will continue to demonstrate meaningful growth potential across a broad array of medical specialties. At current valuation levels, 1.6x 2018 EV/R (peer group: ~3.0x), Invuity would appear undervalued, given the company's significant top-line growth outlook. We rate Invuity shares Buy with a now higher $9 (from $8) target price." (2/15/2017)
Who are some of Invuity's key competitors?
Some companies that are related to Invuity include Utah Medical Products (UTMD), VBI Vaccines (VBIV), Enzymotec (ENZY), GenMark Diagnostics (GNMK), Allergy Therapt (AGYTF), Pieris Pharmaceuticals (PIRS), AAC Holdings (AAC), OrthoPediatrics Corp. (KIDS), Ovid Therapeutc (OVID), Vital Therapies (VTL), Zymeworks (ZYME), MDxhealth SA (MXDHF), XOMA Corporation (XOMA), Helius Medical Technologies (HSDT), Foamix Pharmaceuticals (FOMX), Veracyte (VCYT), Chimerix (CMRX) and Nabriva Therapeutics AG (NBRV).
When did Invuity IPO?
(IVTY) raised $48 million in an IPO on the week of June 15th 2015. The company issued 4,000,000 shares at a price of $12.00 per share. Piper Jaffray, Leerink Partners and Stifel acted as the underwriters for the IPO and William Blair was co-manager.
Who owns Invuity stock?
Invuity's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Discovery Group I LLC (7.34%),
DISCOVERY GROUP I, LLC
(7.10%), Lyon Street Capital LLC (5.15%), Cowen Prime Services LLC (2.67%), B. Riley Financial Inc. (1.75%) and Granite Investment Partners LLC (1.01%). Company insiders that own Invuity stock include Alex Vayser, Eric W Roberts, Gregory T Lucier, James E Flynn, James H Mackaness, Philip M Sawyer, Reza Zadno and Robert Gerberich. View Institutional Ownership Trends for Invuity.
Who sold Invuity stock? Who is selling Invuity stock?
Invuity's stock was sold by a variety of institutional investors in the last quarter, including B. Riley Financial Inc., Granite Investment Partners LLC and Cowen Prime Services LLC. Company insiders that have sold Invuity company stock in the last year include James E Flynn and Reza Zadno. View Insider Buying and Selling for Invuity.
Who bought Invuity stock? Who is buying Invuity stock?
Invuity's stock was bought by a variety of institutional investors in the last quarter, including Discovery Group I LLC, Lyon Street Capital LLC and CAPROCK Group Inc.. Company insiders that have bought Invuity stock in the last two years include Eric W Roberts, Gregory T Lucier and James H Mackaness. View Insider Buying and Selling for Invuity.
How do I buy Invuity stock?
Shares of Invuity can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Invuity's stock price today?
One share of Invuity stock can currently be purchased for approximately $8.05.
How big of a company is Invuity?
Invuity has a market capitalization of $144.83 million and generates $32.46 million in revenue each year. The medical instruments supplier earns ($40,600,000.00) in net income (profit) each year or ($2.47) on an earnings per share basis. Invuity employs 172 workers across the globe.
How can I contact Invuity?
MarketBeat Community Rating for Invuity (NASDAQ IVTY)MarketBeat's community ratings are surveys of what our community members think about Invuity and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Invuity's mailing address is 444 DE HARO STREET, San Francisco CA, 94107. The medical instruments supplier can be reached via phone at 415-655-2100 or via email at firstname.lastname@example.org.
Analysts' Consensus Ratings for Invuity (NASDAQ:IVTY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$11.67 (44.93% upside)|Consensus Price Target History for Invuity (NASDAQ:IVTY)
Analysts' Ratings History for Invuity (NASDAQ:IVTY)
(Data available from 11/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/10/2017||Piper Jaffray Companies||Reiterated Rating||Buy||$12.00||N/A|
|9/26/2017||Northland Securities||Reiterated Rating||Buy||$13.00||Low|
|5/23/2017||William Blair||Reiterated Rating||Buy||Low|
|4/27/2017||Stifel Nicolaus||Reiterated Rating||Buy -> Buy||$9.00 -> $10.00||High|
|9/19/2016||Lake Street Capital||Initiated Coverage||Buy||$18.00 -> $18.00||N/A|
|8/29/2016||Craig Hallum||Initiated Coverage||Buy||$25.00||N/A|
|6/23/2016||Leerink Swann||Reiterated Rating||Buy||$15.00||N/A|
Earnings History for Invuity (NASDAQ:IVTY)Earnings History by Quarter for Invuity (NASDAQ IVTY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/7/2017||Q3 2017||($0.56)||($0.52)||$9.87 million||$9.60 million||View||N/A|
|7/25/2017||Q2 2017||($0.54)||($0.61)||$10.30 million||$9.77 million||View||N/A|
|4/26/2017||Q1 2017||($0.61)||($0.64)||$8.71 million||$9.02 million||View||N/A|
|2/14/2017||Q4 2016||($0.56)||($0.56)||$9.14 million||$9.36 million||View||Listen|
|11/3/2016||Q3||($0.62)||($0.56)||$9.29 million||$8.48 million||View||Listen|
|7/19/2016||Q2||($0.81)||($0.76)||$8.04 million||$8.20 million||View||Listen|
|5/5/2016||Q1||($0.68)||($0.90)||$6.10 million||$6.40 million||View||Listen|
|2/24/2016||Q4||($0.72)||($0.76)||$5.77 million||$6.25 million||View||Listen|
|11/10/2015||Q315||($0.96)||($0.69)||$5.05 million||$5.60 million||View||Listen|
|8/11/2015||Q215||($0.75)||($3.20)||$4.55 million||$4.70 million||View||Listen|
Earnings Estimates for Invuity (NASDAQ:IVTY)
2017 EPS Consensus Estimate: ($1.87)
2018 EPS Consensus Estimate: ($1.59)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Invuity (NASDAQ:IVTY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Invuity (NASDAQ IVTY)
Insider Ownership Percentage: 10.50%Insider Trades by Quarter for Invuity (NASDAQ IVTY)
Institutional Ownership Percentage: 65.72%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/18/2017||Eric W Roberts||Director||Buy||6,500||$7.07||$45,955.00|| |
|5/15/2017||Eric W Roberts||Director||Buy||5,000||$7.88||$39,400.00|| |
|5/9/2017||Eric W Roberts||Director||Buy||2,000||$8.80||$17,600.00|| |
|5/3/2017||Reza Zadno||Director||Sell||4,000||$9.16||$36,640.00|| |
|12/14/2016||James E Flynn||Insider||Sell||184,796||$6.22||$1,149,431.12|| |
|11/8/2016||James H Mackaness||CFO||Buy||1,700||$5.75||$9,775.00|| |
|10/17/2016||Eric W Roberts||Director||Sell||1,000||$12.08||$12,080.00|| |
|10/6/2016||Philip M Sawyer||Insider||Sell||900||$13.01||$11,709.00|| |
|10/6/2016||Robert Gerberich||VP||Sell||1,500||$12.72||$19,080.00|| |
|10/3/2016||Alex Vayser||Insider||Sell||3,000||$13.18||$39,540.00|| |
|9/22/2016||Eric W Roberts||Director||Sell||2,201||$14.00||$30,814.00|| |
|9/15/2016||Eric W Roberts||Director||Sell||5,000||$13.47||$67,350.00|| |
|9/2/2016||Eric W Roberts||Director||Sell||26,839||$14.00||$375,746.00|| |
|9/1/2016||Alex Vayser||Insider||Sell||7,000||$14.00||$98,000.00|| |
|8/24/2016||Alex Vayser||Insider||Sell||9,000||$12.78||$115,020.00|| |
|8/24/2016||Robert Gerberich||VP||Sell||10,500||$12.53||$131,565.00|| |
|8/23/2016||Eric W Roberts||Director||Sell||5,000||$12.00||$60,000.00|| |
|7/21/2016||Alex Vayser||Insider||Sell||12,000||$12.00||$144,000.00|| |
|7/21/2016||Eric W Roberts||Director||Sell||42,000||$12.00||$504,000.00|| |
|6/10/2016||Gregory T Lucier||Director||Buy||8,442||$7.56||$63,821.52|| |
|6/7/2016||Gregory T Lucier||Director||Buy||5,601||$7.00||$39,207.00|| |
|6/6/2016||Gregory T Lucier||Director||Buy||26,728||$6.90||$184,423.20|| |
|5/18/2016||James H Mackaness||CFO||Buy||2,000||$5.08||$10,160.00|| |
Headline Trends for Invuity (NASDAQ:IVTY)
Latest Headlines for Invuity (NASDAQ IVTY)
|Invuity, Inc. (IVTY) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - November 16 at 11:02 AM
|Invuity to Present at Upcoming Investor Conferences|
finance.yahoo.com - November 15 at 3:27 AM
|Invuity, Inc. (IVTY) Earns Buy Rating from Piper Jaffray Companies|
www.americanbankingnews.com - November 11 at 9:42 AM
|Q4 2017 EPS Estimates for Invuity, Inc. Cut by Analyst (IVTY)|
www.americanbankingnews.com - November 10 at 3:04 PM
|Brokers Set Expectations for Invuity, Inc.'s FY2017 Earnings (IVTY)|
www.americanbankingnews.com - November 10 at 2:42 PM
|Leerink Swann Comments on Invuity, Inc.'s Q1 2018 Earnings (IVTY)|
www.americanbankingnews.com - November 9 at 11:43 AM
|Invuity, Inc. (IVTY) Posts Earnings Results, Beats Estimates By $0.04 EPS|
www.americanbankingnews.com - November 8 at 6:26 PM
|Invuity Inc to Host Earnings Call|
finance.yahoo.com - November 8 at 10:43 AM
|Invuity Reports 2017 Third Quarter Financial Results|
finance.yahoo.com - November 8 at 10:43 AM
|Invuity reports 3Q loss|
finance.yahoo.com - November 8 at 10:43 AM
|Edited Transcript of IVTY earnings conference call or presentation 7-Nov-17 10:00pm GMT|
finance.yahoo.com - November 8 at 10:43 AM
|Invuity, Inc. (IVTY) Expected to Announce Earnings of -$0.55 Per Share|
www.americanbankingnews.com - November 5 at 3:21 AM
|Invuity Announces 2017 Third Quarter Financial Results and Conference Call Date|
finance.yahoo.com - October 24 at 5:23 PM
|Invuity, Inc. (IVTY) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - October 22 at 11:02 AM
|Invuity, Inc. (IVTY) Set to Announce Quarterly Earnings on Thursday|
www.americanbankingnews.com - October 19 at 2:32 AM
|Invuity Strengthens Senior Management With Appointment of Chief Human Resources Officer|
finance.yahoo.com - October 18 at 2:51 AM
|Invuity, Inc. (IVTY) Expected to Post Q1 2018 Earnings of ($0.47) Per Share|
www.americanbankingnews.com - September 28 at 10:40 AM
|Invuity, Inc. (IVTY) Earns "Buy" Rating from Northland Securities|
www.americanbankingnews.com - September 27 at 5:32 PM
|Invuity Draws $10 Million Second Tranche Of Term Loan|
www.thestreet.com - September 27 at 4:55 PM
|Invuity, Inc. (IVTY) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - September 27 at 11:00 AM
|Invuity Announces Full Commercial Launch of PhotonBlade™|
finance.yahoo.com - September 25 at 6:36 PM
|Ekso Bionics Holdings (EKSO) & Invuity (IVTY) Critical Contrast|
www.americanbankingnews.com - September 18 at 2:30 PM
|Invuity to Present at Cantor Fitzgerald Global Healthcare Conference|
finance.yahoo.com - September 14 at 6:39 AM
|Invuity (IVTY) and Ekso Bionics Holdings (EKSO) Head-To-Head Analysis|
www.americanbankingnews.com - September 11 at 10:40 AM
|Invuity (IVTY) and Ekso Bionics Holdings (EKSO) Financial Review|
www.americanbankingnews.com - September 5 at 10:22 AM
|Invuity, Inc. (IVTY) Receives Average Rating of "Hold" from Brokerages|
www.americanbankingnews.com - September 2 at 10:40 AM
|Invuity, Inc. (IVTY) Appoints Daniel Wolterman to Board|
www.streetinsider.com - September 1 at 1:09 AM
|Daniel Wolterman Joins Invuity’s Board of Directors|
finance.yahoo.com - August 31 at 6:25 AM
|Ekso Bionics Holdings (EKSO) vs. Invuity (IVTY) Head-To-Head Comparison|
www.americanbankingnews.com - August 28 at 8:10 PM
|Invuity, Inc. (IVTY) Sees Significant Increase in Short Interest|
www.americanbankingnews.com - August 28 at 1:20 AM
|$10.15 Million in Sales Expected for Invuity, Inc. (IVTY) This Quarter|
www.americanbankingnews.com - August 23 at 11:06 AM
|ETFs with exposure to Invuity, Inc. : August 8, 2017|
finance.yahoo.com - August 8 at 7:43 PM
|Invuity, Inc. (IVTY) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - August 8 at 11:04 AM
|Head to Head Comparison: Invuity (NASDAQ:IVTY) and Strata Skin Sciences (SSKN)|
www.americanbankingnews.com - July 30 at 7:27 AM
|William Blair Equities Analysts Reduce Earnings Estimates for Invuity, Inc. (NASDAQ:IVTY)|
www.americanbankingnews.com - July 28 at 12:39 PM
|Leerink Swann Weighs in on Invuity, Inc.'s Q3 2017 Earnings (NASDAQ:IVTY)|
www.americanbankingnews.com - July 28 at 11:27 AM
|Financial Comparison: Invuity (NASDAQ:IVTY) vs. Strata Skin Sciences (SSKN)|
www.americanbankingnews.com - July 28 at 8:10 AM
|Invuity, Inc. :IVTY-US: Earnings Analysis: Q2, 2017 By the Numbers : July 27, 2017|
finance.yahoo.com - July 27 at 11:29 PM
|Edited Transcript of IVTY earnings conference call or presentation 25-Jul-17 9:00pm GMT|
finance.yahoo.com - July 27 at 5:19 AM
|Invuity, Inc. (NASDAQ:IVTY) Announces Quarterly Earnings Results, Misses Estimates By $0.07 EPS|
www.americanbankingnews.com - July 26 at 1:06 PM
|Investor Network: Invuity Inc to Host Earnings Call|
finance.yahoo.com - July 25 at 8:53 PM
|Invuity Reports 2017 Second Quarter, Six-Month Financial Results|
finance.yahoo.com - July 25 at 8:53 PM
|Invuity reports 2Q loss|
finance.yahoo.com - July 25 at 8:53 PM
|Financial Comparison: Unilife Corp (UNIS) & Invuity (NASDAQ:IVTY)|
www.americanbankingnews.com - July 21 at 10:16 AM
|Invuity, Inc. (NASDAQ:IVTY) Expected to Announce Quarterly Sales of $10.30 Million|
www.americanbankingnews.com - July 14 at 4:21 PM
|Strata Skin Sciences (SSKN) vs. Invuity (NASDAQ:IVTY) Head-To-Head Contrast|
www.americanbankingnews.com - July 14 at 12:57 PM
|Invuity, Inc. (NASDAQ:IVTY) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - July 14 at 11:18 AM
|Invuity Inc. Showcased PhotonBlade at Premier Inc.’s Annual Breakthroughs Conference|
finance.yahoo.com - July 13 at 3:48 AM
|Invuity, Inc. (IVTY) Expected to Post Earnings of -$0.54 Per Share|
www.americanbankingnews.com - July 12 at 8:18 AM
|Invuity Announces 2017 Second Quarter Financial Results and Conference Call Date|
finance.yahoo.com - July 12 at 12:13 AM
Invuity (NASDAQ IVTY) Chart for Friday, November, 17, 2017